Attached files
| file | filename |
|---|---|
| EX-99.1 - GENVEC INC | v198390_ex99-1.htm |
|
|
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of
Report (Date of earliest event reported): September 30,
2010
GENVEC,
INC.
(Exact
name of registrant as specified in its charter)
|
Delaware
|
0-24469
|
23-2705690
|
||
|
(State
or other jurisdiction
|
(Commission
|
(IRS
Employer
|
||
|
of
Incorporation)
|
File
Number)
|
Identification
No.)
|
|
65 West Watkins Mill Road, Gaithersburg,
Maryland
|
20878
|
|
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
(240) 632
0740
(Former
name or former address, if changed since last report)
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of
the registrant under any of the following provisions:
¨ Written communications
pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨ Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨ Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
¨ Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
|
INFORMATION
TO BE INCLUDED IN THE REPORT
Section
1 – Registrant’s Business and Operations
Item
1.01 Entry
into a Material Definitive Agreement
On
September 30, 2010, SAIC-Frederick, Inc., a subsidiary of Science Applications
International Corporation (“SAIC”), exercised its first option period under a
previously announced four year agreement, dated November 3, 2009 (the
“Agreement”), with GenVec, Inc. (the “Company”) for the development of
influenza and HIV vaccines in support of the Vaccine Research Center of
the National Institute of Allergy and Infectious Diseases, part of the National
Institutes of Health, pursuant to SAIC’s grant from the National Cancer
Institute. The Agreement provides for payments to the Company of up to
approximately $24 million over four years, of which approximately $3.1 million
was awarded during the first year of activities under the Agreement, which ended
September 30, 2010, and approximately $3.5 million is expected to be received
during the second year of activities under the Agreement as a result of the
exercise of the first option period, which runs through September 30, 2011. The
funds received pursuant to the Agreement will continue to support the
development of new HIV and influenza vaccine candidates based on the Company’s
proprietary adenovirus vector and production cell line
technologies.
On
October 6, 2010, the Company issued a press release announcing SAIC’s exercise
of its first option period. A copy of the press release is attached
to this current report as Exhibit
99.1 and is incorporated herein by reference.
Section
9 – Financial Statements and Exhibits
Item
9.01 Financial
Statements and Exhibits
Exhibit
99.1 GenVec, Inc.
Press Release issued on October 6, 2010
2
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
|
GENVEC,
INC.
|
||
|
Date:
October 6, 2010
|
By:
|
/s/ DOUGLAS J. SWIRSKY
|
|
Douglas J. Swirsky
|
||
|
Senior Vice President, Chief Financial Officer, Treasurer
and Corporate Secretary
|
3
EXHIBIT
INDEX
|
99.1
|
GenVec,
Inc. Press Release issued on October 6,
2010
|
4